Almatica Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ALMATICA, and what generic alternatives to ALMATICA drugs are available?
ALMATICA has fourteen approved drugs.
There are nine US patents protecting ALMATICA drugs.
There are fifty-eight patent family members on ALMATICA drugs in thirty countries and forty-three supplementary protection certificates in sixteen countries.
Drugs and US Patents for Almatica
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Almatica | MACRODANTIN | nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 016620-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
Almatica | FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride | TABLET;ORAL | 202133-001 | Oct 6, 2011 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
Almatica | NAPRELAN | naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 020353-003 | Jan 5, 1996 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
Almatica | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
Almatica | TENORETIC 100 | atenolol; chlorthalidone | TABLET;ORAL | 018760-001 | Jun 8, 1984 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
Almatica | GRALISE | gabapentin | TABLET;ORAL | 022544-001 | Jan 28, 2011 | BX | RX | Yes | Yes | 8,192,756 | See Plans and Pricing | Y | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Almatica
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Almatica | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | 3,934,032 | See Plans and Pricing |
Almatica | TENORMIN | atenolol | TABLET;ORAL | 018240-004 | Apr 9, 1990 | 3,934,032 | See Plans and Pricing |
Almatica | GRALISE | gabapentin | TABLET;ORAL | 022544-002 | Jan 28, 2011 | 8,333,992 | See Plans and Pricing |
Almatica | ZESTRIL | lisinopril | TABLET;ORAL | 019777-004 | May 19, 1988 | 4,374,829*PED | See Plans and Pricing |
Almatica | GRALISE | gabapentin | TABLET;ORAL | 022544-002 | Jan 28, 2011 | 6,635,280 | See Plans and Pricing |
Almatica | GRALISE | gabapentin | TABLET;ORAL | 022544-001 | Jan 28, 2011 | 8,252,332 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALMATICA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Tablets | 450 mg | ➤ Subscribe | 2013-02-28 |
➤ Subscribe | Tablets | 300 mg and 600 mg | ➤ Subscribe | 2011-10-31 |
Premature patent expirations for ALMATICA
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
See Plans and Pricing | See Plans and Pricing |
International Patents for Almatica Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2005267738 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2014110245 | See Plans and Pricing |
Croatia | P20210236 | See Plans and Pricing |
European Patent Office | 2943185 | See Plans and Pricing |
Canada | 2897302 | See Plans and Pricing |
Denmark | 1439825 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Almatica Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2316456 | CA 2017 00062 | Denmark | See Plans and Pricing | PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330 |
0984957 | PA2011005,C0984957 | Lithuania | See Plans and Pricing | PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126 |
0656775 | 28/2000 | Austria | See Plans and Pricing | PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201 |
2316456 | 2017C/064 | Belgium | See Plans and Pricing | PRODUCT NAME: NALTREXONE/BUPROPION; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330 |
1411900 | 122012000052 | Germany | See Plans and Pricing | PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 |
0984957 | SPC/GB11/013 | United Kingdom | See Plans and Pricing | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |